TELO Stock Chart & Stats
$1.35
-$0.17(-3.74%)
At close: 4:00 PM EST
$1.35
-$0.17(-3.74%)
Day’s Range― - ―
52-Week Range$1.05 - $3.10
Previous CloseN/A
Volume44.80K
Average Volume (3M)126.17K
Market Cap
$89.41M
Enterprise Value$37.42M
Total Cash (Recent Filing)$5.56M
Total Debt (Recent Filing)$202.87K
Price to Earnings (P/E)―
Beta1.54
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding68,774,956
10 Day Avg. Volume203,400
30 Day Avg. Volume126,172
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)7.12
Price to Sales (P/S)0.00
P/FCF Ratio-11.41
Enterprise Value/Market Cap0.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.06
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$1.50M
Telomir Pharmaceuticals, Inc. News
TELO FAQ
What was Telomir Pharmaceuticals, Inc.’s price range in the past 12 months?
Telomir Pharmaceuticals, Inc. lowest stock price was $1.05 and its highest was $3.10 in the past 12 months.
What is Telomir Pharmaceuticals, Inc.’s market cap?
Telomir Pharmaceuticals, Inc.’s market cap is $89.41M.
When is Telomir Pharmaceuticals, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Telomir Pharmaceuticals, Inc.’s earnings last quarter?
Currently, no data Available
Is Telomir Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Telomir Pharmaceuticals, Inc.’s price is currently Overvalued.
Does Telomir Pharmaceuticals, Inc. pay dividends?
Telomir Pharmaceuticals, Inc. does not currently pay dividends.
What is Telomir Pharmaceuticals, Inc.’s EPS estimate?
Telomir Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Telomir Pharmaceuticals, Inc. have?
Telomir Pharmaceuticals, Inc. has 68,774,956 shares outstanding.
What happened to Telomir Pharmaceuticals, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Telomir Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in TELO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Telomir Pharmaceuticals, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
TELO Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.36%
12-Months-Change
Fundamentals
Return on Equity
-201.23%
Trailing 12-Months
Asset Growth
1078.68%
Trailing 12-Months
Company Description
Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.
Technical Analysis
Tempest Therapeutics
―
Verrica Pharmaceuticals
―
Lantern Pharma
―
CalciMedica
―
Century Therapeutics
―
Ownership Overview
10.64% Insiders
1.72% Mutual Funds
0.17% Other Institutional Investors
85.92% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---